Exact Sciences
Market Cap
US$10.5b
Last Updated
2019/11/11 23:38 UTC
Data Sources
Company Financials +
Executive Summary
Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States.
Snowflake
High growth potential with adequate balance sheet.
Similar Companies
Share Price & News
How has Exact Sciences's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: EXAS's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
-9.0%
EXAS
1.0%
US Biotechs
0.3%
US Market
1 Year Return
18.0%
EXAS
6.7%
US Biotechs
12.5%
US Market
Return vs Industry: EXAS exceeded the US Biotechs industry which returned 6.7% over the past year.
Return vs Market: EXAS exceeded the US Market which returned 12.5% over the past year.
Shareholder returns
| EXAS | Industry | Market | |
|---|---|---|---|
| 7 Day | -9.0% | 1.0% | 0.3% |
| 30 Day | -12.9% | 11.0% | 4.1% |
| 90 Day | -33.5% | 5.2% | 5.6% |
| 1 Year | 18.0%18.0% | 7.6%6.7% | 15.0%12.5% |
| 3 Year | 357.6%357.6% | 12.4%8.9% | 49.1%39.4% |
| 5 Year | 250.7%250.7% | 6.4%1.4% | 62.8%44.7% |
Price Volatility Vs. Market
How volatile is Exact Sciences's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
Earnings Release: Here's Why Analysts Cut Their Exact Sciences Corporation Price Target To US$1273 weeks ago | Simply Wall St
Does Exact Sciences Corporation's (NASDAQ:EXAS) CEO Salary Reflect Performance?1 month ago | Simply Wall St
The Exact Sciences (NASDAQ:EXAS) Share Price Has Soared 419%, Delighting Many ShareholdersValuation
Is Exact Sciences undervalued compared to its fair value and its price relative to the market?
44.9%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: EXAS ($80.53) is trading below our estimate of fair value ($146.24)
Significantly Below Fair Value: EXAS is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: EXAS is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: EXAS is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate EXAS's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: EXAS is overvalued based on its PB Ratio (14x) compared to the US Biotechs industry average (2.8x).
Next Steps
Future Growth
How is Exact Sciences forecast to perform in the next 1 to 3 years based on estimates from 12 analysts?
103.3%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: EXAS is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.7%).
Earnings vs Market: EXAS is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: EXAS's is expected to become profitable in the next 3 years.
Revenue vs Market: EXAS's revenue (49.6% per year) is forecast to grow faster than the US market (7.2% per year).
High Growth Revenue: EXAS's revenue (49.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if EXAS's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Exact Sciences performed over the past 5 years?
-9.5%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: EXAS has a high level of non-cash earnings.
Growing Profit Margin: EXAS's current net profit margins (-29.8%) are higher than last year (-35.8%).
Past Earnings Growth Analysis
Earnings Trend: EXAS is unprofitable, and losses have increased over the past 5 years at a rate of -9.5% per year.
Accelerating Growth: Unable to compare EXAS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EXAS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (67.8%).
Return on Equity
High ROE: EXAS has a negative Return on Equity (-28.85%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is Exact Sciences's financial position?
Financial Position Analysis
Short Term Liabilities: EXAS's short term assets ($1.3B) exceeds its short term liabilities ($480.7M)
Long Term Liabilities: EXAS's short term assets (1.3B) exceeds its long term liabilities (530.3M)
Debt to Equity History and Analysis
Debt Level: EXAS's debt to equity ratio (109.2%) is considered high
Reducing Debt: EXAS had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Balance Sheet
Inventory Level: EXAS has a high level of physical assets or inventory.
Debt Coverage by Assets: EXAS's debt is covered by short term assets (assets are 1.6x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: EXAS has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if EXAS has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Next Steps
Dividend
What is Exact Sciences's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate EXAS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate EXAS's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if EXAS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if EXAS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of EXAS's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
What is the CEO of Exact Sciences's salary, the management and board of directors tenure and is there insider trading?
4.8yrs
Average management tenure
CEO
Kevin Conroy (53yo)
10.6yrs
Tenure
US$6,991,997
Compensation
Mr. Kevin T. Conroy serves as Director of Adaptive Biotechnologies Corporation since April 2019. Mr. Conroy serves as Director at ARYA Sciences Acquisition Corp. Mr. Conroy has been the Chief Executive Off ...
CEO Compensation Analysis
Compensation vs Market: Kevin's total compensation ($USD6.99M) is below average for companies of similar size in the US market ($USD11.12M).
Compensation vs Earnings: Kevin's compensation has been consistent with company performance over the past year.
Management Age and Tenure
4.8yrs
Average Tenure
53yo
Average Age
Experienced Management: EXAS's management team is considered experienced (4.8 years average tenure).
Board Age and Tenure
5.0yrs
Average Tenure
64yo
Average Age
Experienced Board: EXAS's board of directors are considered experienced (5 years average tenure).
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.6%.
Management Team
D. Coward (54yo)
Chief Administrative Officer
- Tenure: 1.3yrs
- Compensation: US$2.09m
Gary Frings
Chief Information Officer
- Tenure: 4.8yrs
Graham Lidgard (70yo)
Chief Science Officer
- Tenure: 10.3yrs
- Compensation: US$2.08m
Kevin Conroy (53yo)
Chairman of the Board
- Tenure: 10.6yrs
- Compensation: US$6.99m
Jeff Elliott (41yo)
Chief Financial Officer
- Tenure: 3yrs
- Compensation: US$1.98m
Tim Caprez
Chief Compliance Counsel & VP
- Tenure: 4.8yrs
Ana Hooker (53yo)
Senior Vice President of Operations
- Tenure: 4.8yrs
Mark Stenhouse (52yo)
President of Cologuard
- Tenure: 1.6yrs
- Compensation: US$3.86m
Megan Jones
Associate Manager of Investor Relations
- Tenure: 0yrs
Vic Parker
Head of Sales
- Tenure: 0.9yrs
Board Members
Andy Slavitt (52yo)
Director
- Tenure: 0.3yrs
Dan Levangie (68yo)
Independent Director
- Tenure: 9.3yrs
- Compensation: US$272.47k
Mike Wyzga (64yo)
Independent Director
- Tenure: 4.8yrs
- Compensation: US$274.97k
Kay Napier Zanotti (64yo)
Independent Director
- Tenure: 10.6yrs
- Compensation: US$269.97k
Kevin Conroy (53yo)
Chairman of the Board
- Tenure: 10.6yrs
- Compensation: US$6.99m
Eli Casdin
Independent Director
- Tenure: 2yrs
- Compensation: US$474.41k
Kathleen Sebelius (71yo)
Independent Director
- Tenure: 0.7yrs
Tom Carey (57yo)
Independent Director
- Tenure: 6.6yrs
- Compensation: US$256.47k
Jim Doyle (73yo)
Independent Director
- Tenure: 5.3yrs
- Compensation: US$266.47k
Pierre Jacquet
Director
- Tenure: 0.3yrs
Company Information
Exact Sciences Corporation's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Exact Sciences Corporation
- Ticker: EXAS
- Exchange: NasdaqCM
- Founded: 1995
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$10.455b
- Shares outstanding: 129.83m
- Website: https://www.exactsciences.com
Number of Employees
Location
- Exact Sciences Corporation
- 441 Charmany Drive
- Madison
- Wisconsin
- 53719
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| EXAS | NasdaqCM (Nasdaq Capital Market) | Yes | Common Stock | US | USD | Jan 2001 |
| EXK | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Jan 2001 |
Biography
Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a n ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/11/11 23:38 |
| End of Day Share Price | 2019/11/11 00:00 |
| Earnings | 2019/09/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.